Schedule 13G/A
ANIK Schedule 13G/A filing by Vanguard Capital Management
Vanguard Capital Management reported beneficial ownership of 659.2K shares, representing 12% of Anika Therapeutics, Inc. in this filing.
FiledJul 31, 2026
Ownership dateJun 30, 2026
Reported shares659.2K
Reported ownership12%
Ownership details
Voting and dispositive power reported in the filing
These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.
Sole voting power
87.1K
Shared voting power
659.2K
Sole dispositive power
659.2K
Shared dispositive power
659.2K
Price context
Price dates alongside the ownership filing
Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.
Close near filing date$19.28as of Jul 31, 2026
Latest tracked price$19.61as of Aug 4, 2026
Source
Original filing and accession
Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.
- Reporting filer
- Vanguard Capital Management
- CIK
- CIK0002100119
- Accession
- 0002100119-26-001342
- Form
- Schedule 13G/A
Read the filing in context